Tyrosinase expression as a molecular marker for investigating the presence of circulating tumor cells in melanoma patients

Current Cancer Drug Targets

Volumn 10, Issue 5, 2010, Pages 529-538

  Gradilone, A ^a   Cigna, E ^a   Agliano A M ^a   Frati, L ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Melanoma; Peripheral blood; RT PCR; Tyrosinase

Indexed keywords

GLYCOPROTEIN GP 100; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; RNA; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CUTANEOUS MALIGNANT MELANOMA; GENE AMPLIFICATION; HUMAN; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT RESPONSE; TUMOR CELL; BLOOD; REVIEW; TUMOR EMBOLISM;

HUMANS; MELANOMA; MONOPHENOL MONOOXYGENASE; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77956544819     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791517136     Document Type: Article

References (91)

1. Perlis, C.; Herlyn, M. Recent advances in melanoma biology. Oncologist 2004, 9, 182-7.
2. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
3. Gimotty, P. A.; Guerry, D.; Ming, M. E.; Elenitsas, R.; Xu, X.; Czerniecki, B.; Spitz, F.; Schuchter, L.; Elder, D. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J. Clin. Oncol. 2004, 22, 3668-3676.
4. Kirkwood, J. M.; Moschos, S.; Wang, W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin. Cancer Res. 2006, 12, 2331s-2336s.
5. Balch, C. M.; Buzaid, A. C.; Soong, S.J.; Atkins, M. B.; Cascinelli, N.; Coit, D. G.; Fleming, I. D.; Gershenwald, J. E.; Houghton, A. Jr.; Kirkwood, J. M.; McMasters, K. M.; Mihm, M. F.; Morton, D.L.; Reintgen, D. S.; Ross, M. I.; Sober, A.; Thompson, J. A.; Thompson, J. F. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001, 19, 3635-3648.
6. Foa, C.; Aubert, C. Cellular localization of Tyrosinase in human malignant melanoma cell lines. J. Invest. Dermatol. 1977, 68, 369-378.
7. Kwon, B. S.; Haq, A. K.; Pomerantz, S. H.; Halaban, R. Isolation and sequence of a cDNA clone for human Tyrosinase that maps at the mouse c-albino locus. Proc. Natl. Acad. Sci. USA 1987, 84, 7473-7477.
8. Smith, B.; Selby, P.; Southgate, J.; Pittmann, K.; Bradley, C.; Blair, G. E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991, 351, 1905-1910.
9. Brossart, P.; Keilholz, U.; Willhauck, M.; Scheibenbogen, C.; Möhler, T.; Hunstein, W. Hematogenous spread of malignant melanoma cells in different stages of disease. J. Invest. Dermatol. 1993, 101, 887-889.
10. Mellado, B.; Colomer, D.; Castel, T.; Muñoz, M.; Carballo, E.; Galán, M.; Mascaró, J. M.; Vives-Corrons, J. L.; Grou, J. J.; Estapé, J. Detection of circulating neoplastic cells by RT-PCR in malignant melanoma: Correlation with clinical stage and prognosis. J. Clin. Oncol. 1996, 14, 2091-2097.
11. Mellado, B.; Gutierrez, L.; Castel, T.; Colomer, D.; Fontanillas, M.; Castro, J.; Estape, J. Prognostic significance of the detection of circulating malignant cells by RT-PCR in long-term clinically disease-free melanoma patients. Clin. Cancer Res. 1999, 5, 1843-1848.
12. Reinhold, U.; Ludtke-Handjery, H. C.; Schnautz, S.; Kreysel, H. W.; Abken, H. The analysis of Tyrosinase-specifc mRNA in blood samples of melanoma patients by RTPCR is not a useful test for metastatic tumor progression. J. Invest. Dermatol. 1997, 108, 166-169.
13. Keilholz, U.; Willhauck, M.; Rimoldi, D.; Brasseur, F; Dummer, W.; Rass, K.; de Vries, T.; Blaheta, J.; Voit, C.; Lethé, B.; Burchill, S. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: A quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur. J. Cancer 1998, 34, 750-753.
14. Battayani, Z.; Grob, J. J.; Xerri, L.; Noe, C.; Zarour, H.; Houvaeneghel, G.; Delpero, J. R.; Birmbaum, D.; Hassoun, J.; Bonerandi, J. J. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch. Dermatol. 1995, 131, 443-447.
15. Kunter, U.; Buer, J.; Probst, M.; Duensing, S.; Dallmann, I.; Grosse, J.; Kirchner, H.; Schluepen, E. M.; Volkenandt, M.; Ganser, A.; Jens Atzpodien, J. Peripheral blood Tyrosinase messenger RNA detection and survival in malignant melanoma. J. Natl. Cancer Inst. 1996, 88, 590-594, 1996.
16. Farthmann, B.; Eberle, J.; Krasagakis, K.; Gstöttner, M.; Wanf, N.; Bisson, S.; Orfanos, C. E. RT-PCR Tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J. Invest. Dermatol. 1998, 110, 263-267.
17. Curry, B. J.; Myers, K.; Hersey, P. Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma. J. Clin. Oncol. 1998, 16, 1760-1769.
18. Proebstle, T. M.; Jiang, W.; Hogel, J.; Keilholz, U.; Weber, L.; Voit, C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br. J. Cancer 2000, 82, 118.
19. Aubin, F.; Chtourou, M.; Teyssier, J. R.; Laubriet, A.; Mougin, C. H.; Blanc, D.; Humbert, P. The detection of Tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res. 2000, 10, 113-118.
20. Osella Abate, S.; Savoia, P.; Cambieri, I.; Salomone, B.; Quaglino, P.; Bernengo, M. G. Role of RT-PCR Tyrosinase detection in the monitoring of patients with advanced metastatic melanoma. Melanoma Res. 2000, 10, 545-555.
21. Reinhold, U.; Berkin, C.; Bosserhoff, A. K.; Deutschmann, A.; Garbe, C.; Gläser, R.; Hein, R.; Krähn, G.; Peter, R. U.; Rappl, G.; Schittek, B.; Seiter, S.; Ugurel, S.; Volkenandt, M.; Tilgen, W. Interlaboratory Evaluation of a New Reverse Transcriptase Polymerase Chain Reaction-Based Enzyme-Linked Immunosorbent Assay for the Detection of Circulating Melanoma Cells: A Multicenter Study of the Dermatologic Cooperative Oncology Group. J. Clin. Oncol. 2001, 19, 1723-1727.
22. Tsao, H.; Nadiminti, U.; Sober, A. J.; Bigby, M. A Meta-analysis of Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase mRNA as a Marker for Circulating Tumor Cells in Cutaneous Melanoma. Arch. Dermatol. 2001, 137, 325-333.
23. Szenajch, J.; Jasinski, B.; Synowiec, A.; Kulik, J.; Chomicka, M.; Struzyna, J.; Nowecki, Z.; Rutkowski, P.; Ruka, W.; Kup, W.; Janusz, A.; Siedlecki, J. A.; Wiktor-J drzejczak, W. Prognostic value of multiple reverse transcription-PCR Tyrosinase testing for circulating neoplastic cells in malignant melanoma. Clin. Chem. 2003, 49, 1450-1457.
24. Voit, C.; Kron, M.; Rademaker, J.; Schwürzer-Voit, M.; Sterry, W.; Weber, L.; Özdemir, C.; Proebstle, T.; Keilholz, U. Molecular Staging in Stage II and III Melanoma Patients and Its Effect on Long-Term Survival. J. Clin. Oncol. 2005, 23, 1218-1227.
25. Ranieri, J. M.; Wagner, J. D.; Wiebke, E. A.; Azuaje, R.; Smith, M. L.; Wenck, S.; Daggy, J.; Coleman, J. J. Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma. Plast. Reconstr. Surg. 2005, 115, 1058-1063.
26. Carrillo, E.; Pradosa, J.; Marchala, J. A.; Boulaiz, H.; Martinez A.; Rodr ́iguez-Serrano, F.; Caba, O.; Serrano, S.; Arànega, A. Prognostic value of RT-PCR Tyrosinase detection in peripheral blood of melanoma patients. Disease Markers 2006, 22, 175-181.
27. Quaglino, P.; Osella-Abate, S.; Cappello, N.; Ortoncelli, M.; Nardo, T.; Fierro, M. T.; Cavallo, F.; Savoia, P.; Bernengo, M. G. Prognostic relevance of baseline and sequential peripheral blood Tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res. 2007, 17, 75-82.
28. Visús, C.; Andres, R.; Mayordomo, J. I.; Martinez-Lorenzo, M. J.; Murillo, L.; Sáez-Gutiérrez, B.; Diestre, C.; Marcos, I.; Astier, P.; Godino, J.; Carapeto-Marquez de Prado, F. J.; Larrad, L.; Tres, A. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for Tyrosinase mRNA in patients with melanoma. Melanoma Res. 2007, 17, 83-89.
29. Voit, C. A.; Schäfer-Hesterberg, G.; Kron, M.; van Akkooi, A. C. J.; Rademaker, J.; Lukowsky, A.; Schoengen, A.; Schwürzer-Voit, M.; Sterry, W.; Krause, M.; Röwert-Huber, J.; Eggermont, A. M. M. Impact of Molecular Staging Methods in Primary Melanoma: Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) of Ultrasound-Guided Aspirate of the Sentinel Node Does Not Improve Diagnostic Accuracy, But RT-PCR of Peripheral Blood Does Predict Survival. J. Clin. Oncol. 2008, 26, 5742-5747.
30. Ghossein, R. A.; Coit, D.; Brennan, M.; Zhang, Z. F.; Wang, Y.; Bhattacharya, S.; Houghton, A.; Rosai, J. Prognostic significance of peripheral blood and bone marrow Tyrosinase messenger RNA in malignant melanoma. Clin. Cancer Res. 1998, 4, 419-428.
31. Coulie, P. G.; Brichard, V.; Van Pel, A.; Wolfel, T.; Schneider, J.; Traversari, C.; Mattei, S.; De Plean, E.; Lurquin, C.; Szikora, J. P.; Renauld, J. C.; Boon, T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994, 180, 35-42.
32. Chen, Y. T.; Stockert, E.; Jungbluth, A.; Tsang, S.; Coplan, K. A.; Scanlan, M. J.; Old, L. J. Serological analysis of Melan-A (MART1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. Natl. Acad. Sci. USA 1996, 93, 5915-5919.
33. Curry, B. J.; Myers, K.; Hersey, P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J. Clin. Oncol. 1999, 17, 2562-2571.
34. Schittek, B.; Bodingbauer, Y.; Ellwanger, U.; Blaheta, H. J.; Garbe, C. Amplification of MelanA messenger RNA in addition to Tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br. J. Dermatol. 1999, 141, 30-36.
35. Kulik, J.; Nowecki, Z. I.; Rutkowski, P.; Ruka, W.; Rochowska, M.; Skurzak, H.; Siedlecki, J. A. Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay. Melanoma Res. 2001, 11, 65-73.
36. Brownbridge, G. G.; Gold, J.; Edward, M.; MacKie, R.M. Evaluation of the use of Tyr-specific and melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br. J. Dermatol. 2001, 144, 279-287.
37. Strohal, R.; Mosser, R.; Kittler, H.; Wolff, K.; Jansen, B.; Brna, C.; Stingl, G.; Pehamberger, H. MART-1/Melan-A and Tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression. Melanoma Res. 2001, 11, 543-548.
38. Mocellin, S.; Del Fiore, P.; Guarnieri, L.; Scalerta, R.; Foletto, M.; Chiarion, V.; Pilati, P.; Nitti, D.; Lise, M.; Rossi, C. R. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int. J. Cancer 2004, 111, 741-745.
39. Schmidt, H.; Sorensen, B. S.; Sjoegren, P.; Christensen, I. J.; Fode, K.; Larsen, J.; Nexo, E.; von der Maase, H. Circulating Tyrosinase and MART-1 mRNA does not Independently Predict Relapse or Survival in Patients with AJCC Stage I-II Melanoma. J. Invest. Dermatol. 2006, 126, 849-854.
40. Palmieri, G.; Strazzullo, M.; Ascierto, P. A.; Satriano, S. M.; Daponte, A.; Castello, G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression: Melanoma Cooperative Group. J. Clin. Oncol. 1999, 17, 304-311.
41. Palmieri G.; Satriano, S. M.; Budroni, M.; Cossu, A.; Tanda, F.; Canzanella, S.; Caracò, C.; Simeone, E.; Daponte, A.; Mozzillo, N.; Comella, G.; Castello, G.; Ascierto, P. A. Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer 2006, 6, 266.
42. Hoon, D. S.; Wang, Y.; Dale, P. S.; Conrad, A. J.; Schmid, P.; Garrison, D.; Kuo, C.; Foshag, L. J.; Nizze, A. J.; Morton, D. L. Detection of occult melanoma cells in blood with a multiplemarker polymerase chain reaction assay. J. Clin. Oncol. 1995, 13, 2109-2116.
43. Sarantou, T.; Chi, D. D.; Garrison, D. A.; Conrad, A. J.; Schmid, P.; Morton, D. L.; Hoon, D. S. B. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res. 1997, 57, 1371-1376.
44. Reynolds, S. R.; Albrecht, J.; Shapiro, R. L.; Roses, D. F.; Harris, N. H.; Conrad, A.; Zeleniuch-Jacquotte, A.; Bystryn, J. C. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 2003, 9, 1497-1502.
45. Lehmann, J. M.; Holzmann, B.; Breitbart, E. W.; Schmiegelow, P.; Riethmüller, G.; Johnson, J. P. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res. 1987, 47, 841-845.
46. Lehmann, J. M.; Riethmüller, G.; Johnson, J. P. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc. Natl. Acad. Sci. USA 1989, 86, 9891-9895.
47. Hoon, D. S. B.; Bostick, P.; Kuo, C.; Okamoto, T.; Wang, H. J.; Elashoff, R.; Morton, D. L. Molecular Markers in Blood as Surrogate Prognostic Indicators of Melanoma Recurrence. Cancer Res. 2000, 60, 2253-2257.
48. Palmieri, G.; Ascierto, P. A.; Perrone, F.; Satriano, S. M.; Ottaiano, A.; Da ponte, A.; Napoletano, M.; Caracò, C.; Mozzillo, N.; Melucci, M. T.; Cossu, A.; Tanda, F.; Gallo, C.; Satriano, R. A.; Castello, G. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J. Clin. Oncol. 2003, 21, 767-773.
49. Keilholz, U.; Goldin-Lang, P.; Bechrakis, N. E.; Max, N.; Letsch, A.; Schmittel, A.; Scheibenbogen, C.; Heufelder, K.; Eggermont, A.; Thiel, E. Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by RealTime Reverse Transcriptase-Polymerase Chain Reaction. Clin. Cancer Res. 2004, 10, 1605-1612.
50. Gaugler, B.; Van den Eynde, B.; van der Bruggen, P.; Romero, P.; Gaforio, J. J.; De Plaen, E.; Lethé, B.; Brasseur, F.; Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 1994, 179, 921-930.
51. Sers, C.; Riethmuller, G.; Johnson, J. P. MUC18, a melanoma progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res. 1994, 54, 5689-5694.
52. Pickl, W. F.; Majdic, O.; Fischer, G. F.; Petzelbauer, P.; Faé, I.; Waclavicek, M.; Stöckl, J.; Scheinecker, C.; Vidicki, T.; Aushauer, H.; Johnson, J. P.; Knapp, W. MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. J. Immunol. 1997, 58, 2107-2115.
53. Brown, J. P.; Nishiyama, K.; Hellström, I.; Hellström, K. E. Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. J. Immunol. 1981, 127, 539-546.
54. Rose, T. M.; Plowman, G. D.; Teplow, D.; Dreyer, W. J.; Hellström, K. E.; Brown, J. P. Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc. Natl. Acad. Sci. USA 1986, 83, 1261-1265.
55. Schittek, B.; Blaheta, H. J.; Flörchinger, G.; Sauer, B.; Gaarbe, C. Increased sensitivity for the detection of malignant melanoma cells in peripheral blood using an improved protocol for reverse transcription-polymerase chain reaction. Br. J. Dermatol. 1999, 141, 37-43.
56. Rutkowski, P.; Noweckia, Z. I.; Kulikb, J.; Ruka, W.; Siedlecki, J. A. Molecular staging by multimarker reverse transcriptasepolymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection. Melanoma Res. 2008, 18, 246-252.
57. Wascher, R. A.; Morton, D. L.; Kuo, C.; Elashoff, M. R.; Wang, H. J.; Gerami, M.; Hoon, D. S. B. Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated With a Melanoma Vaccine. J. Clin. Oncol. 2003, 21, 2558-2563.
58. Brossart, P.; Schmier, J.; Krüger, S.; Willhauck, M.; Scheibenbogen, C.; Monier, T.; Keilholz, U. A polymerase chain reaction based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res. 1995, 55, 4065-4068.
59. Schmidt, H.; Sørensen, B. S.; von der Maase, H.; Bang, C.; Agger, R.; Hokland, M.; Nexo, E. Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma. Melanoma Res. 2002, 12, 585-592.
60. Mellado, B.; del Carmen Vela, M.; Colomer, D.; Gutierrez, L.; Castel, T.; Quintó, L.; Fontanillas, M.; Reguart, N.; Domingo-Domènech, J. M.; Montagut, C.; Estapé, J.; Gascón, P. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J. Clin. Oncol. 2002, 20, 4032-4039.
61. Gogas, H.; Kefala, G.; Bafaloukos, D.; Frangia, K.; Polyzos, A.; Pectasides, D.; Tsoutsos, D.; Panagiotou, P.; Ioannovich, J.; Loukopoulos, D. Prognostic significance of the sequential detection of circulating melanoma cells by RT -PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer 2002, 87, 181-186.
62. Schmidt, H.; Sorensen, B. H.; Fode, K.; Nexo, E.; Hans von der Maase, H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res. 2005, 15, 409-416.
63. Burchill, S. A.; Perebolte, L.; Johnston, C.; Top B.; Selby, P. Comparison of the RNA-amplification based methods RT-PCR and NASBA for the detection of circulating tumour cells. Br. J. Cancer 2002, 86, 102-109.
64. Faye R. S.; Aamdal, S.; Høifødt, H. K.; Jacobsen, E.; Holstad, L.; Skovlund, E.; Fodstad, Ø. Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin. Cancer Res. 2004, 10, 4134-4139.
65. Ulmer, A.; Schmidt-Kittler, O.; Fischer, J.; Ellwanger, U.; Rassner, G.; Riethmüller, G.; Fierlbeck, G.; Klein, C. A. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin. Cancer Res. 2004, 10, 531-537.
66. Georgieva, J.; Milling, A.; Orfanos, C. E.; Geilenwe, C. C. Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells. Melanoma Res. 2002, 12, 309-317.
67. Steen, S.; Nemunaitis, J.; Fisher, T.; Kuhn, J. Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proc. (Bayl. Univ. Med. Cent.) 2008, 21, 127-132.
68. Scoggins, C. R.; Ross, M. I.; Reintgen, D. S.; Dirk Noyes, R.; Goydos, J. S.; Beitsch, P. D.; Urist, M. M.; Ariyan, S.; Scott Davidson, B.; Sussman, J. J.; Edwards, M. J.; Martin, R. C. G.; Lewis, A. M.; Stromberg, A. J.; Conrad, A. J.; Hagendoorn, L.; Albrecht, J.; McMasters, K. M. Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma. J. Clin. Oncol. 2006, 24, 2849-2857.
69. Quaglino, P.; Osella-Abate, S.; Savoia, P.; Bernengo, M. G. What is the role of sequential reverse-transcriptase polymerase chain reaction of melanoma-specific mRNA in the peripheral blood of melanoma patients? J. Clin. Oncol. 2007, 25, 1140.
70. Osella-Abate, S.; Savoia, P.; Quaglino, P.; Fierro, M. T.; Leporati, C.; Ortoncelli, M.; Bernengo, M. G. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br. J. Cancer 2003, 89, 1457-1462.
71. Max, N.; Willhauck, M.; Wolf, K.; Thilo, F.; Reinhold, U.; Pawlita, M.; Thiel, E.; Keilholz, U. Reliability of PCR-based detection of occult tumour cells: lessons from real-time RT-PCR. Melanoma Res. 2001, 11, 371-378.
72. Vendittelli, F.; Santonocito, C.; Paradisi, A.; Romitelli, F.; Concolino, P.; Silveri, S. L.; Sisto, T.; Capizzi, R.; Catricalà, C.; Mulè, A.; Di Carlo, A.; Zuppi, C.; Capoluogo, E. A new standardized absolute quantitative RT-PCR method for detection of tyrosinase mRNAs in melanoma patients: technical and operative instructions. Clin. Chim. Acta 2009, 409, 100-105.
73. Holodniy, M.; Kim, S.; Katzenstein, D.; Konrad, M.; Groves, E.; Merigan, T. C. Inhibition of human immunodeficiency virus gene amplification by heparin. J. Clin. Microbiol. 1991, 29, 676-679.
74. Glaser, R.; Rass, K.; Seiter, S.; Hauschild, A.; Christophers, E.; Tilgen, W. Detection of circualting melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J. Clin. Oncol. 1997, 15, 2818-2825.
75. Jung, F. A.; Buzaid, A. C.; Ross, M. I.; Woods, K. V.; Lee, J. J.; Albitar, M.; Grimm, E. A. Evaluation of Tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J. Clin. Oncol. 1997, 15, 12826-2831.
76. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162, 156-159.
77. Johansson, M.; Pisa, E. K.; Törmänen, V.; Årstrand, K.; Kågedal, B. Quantitative Analysis of Tyrosinase Transcripts in Blood. Clin. Chem. 2000, 46, 921-927.
78. Van der Velde-Zimmermann, D.; Roijers, J. F. M.; Bouwens-Rombouts, A.; De Weger, R. A.; De Graaf, P. W.; Tilanus, M. G. J.; Van den Tweel, J. G. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am. J. Pathol. 1996, 149, 759-764.
79. Max, N.; Wolf, K.; Thiel, E.; Keilholz, U. Quantitative nested realtime RT-PCR specific for Tyrosinase transcripts to quantitate minimal residual disease. Clin. Chim. Acta 2002, 317, 39-46.
80. Fusi, A.; Collette, S.; Busse, A.; Suciu, S.; Rietz, A.; Santinami, M.; Kruit, W. H.; Testori, A.; Punt, C. J.; Dalgleish, A. G.; Spatz, A.; Eggermont, A. M.; Keilholz, U. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur. J. Cancer 2009, 45, 3189-3197.
81. Seykora, J. T.; Ji, D.; Elenitsas, R.; Horng, W. H.; Elder, D. E. Gene Expression Profiling of Melanocytic Lesions. Am. J. Dermatopathol. 2003, 25, 6-11.
82. DeRisi, J.; Penland, L.; Brown, P. O.; Bitter, M. L.; Meltzre, P. S.; Ray, M.; Chen Y.; Su Y. A.; Trent, J. M. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 1996, 14, 457-460.
83. Hanekom, G. S.; Johnson, C. A.; Kidson, S. H. An improved and combined reverse transcription-polymerase chain reaction assay for reliable detection of metastatic melanoma cells in peripheral blood. Melanoma Res. 1997, 7, 111-116.
84. Pittman, K.; Burchill, S.; Smith, B.; Southgate, J.; Joffe, J.; Gore, M.; Selby, P. Reverse transcriptase polymerase chain reaction for expression of Tyrosinase to identify malignant melanoma cells in peripheral blood. Ann. Oncol. 1996, 7, 297-301.
85. Foss, A. J. E.; Guille, M. J.; Oceleston, N. L.; Hykin, J. L.; Hungerford, J. L.; Lightman, S. The detection of melanoma cells in peripheral blood by reverse transeription-polymerase chain reaction. Br. J. Cancer 1995, 72, 155-159.
86. Bitisik, O.; Camlica, H.; Duranyildiz, D.; Tas, F.; Kurul, S.; Dalay, N. Detection of circulating melanoma cells by a two-marker polymerase chain reaction assay in relation to therapy. J. Biochem. Mol. Biol. 2003, 36, 173-178.
87. Andrés, R.; Mayordomo, J. I.; Visus, C.; Isla, D.; Godino, J.; Escudero, P.; Saenz, A.; Ortega, E.; Lastra, R.; Lambea, J.; Aguirre, E.; Elosegui, L.; Marcos, I.; Ruiz-Echarri, M.; Millastre, E.; Sáez-Gutierrez, B.; Asin, L.; Vidal, M. J.; Ferrer, A.; Giner, A.; Larrad, L.; Carapeto, F. J.; Tres, A. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma. Am. J. Clin. Oncol. 2008, 31, 335-339.
88. Arenberger, P.; Arenbergerova, M.; Vohradnikova, O.; Kremen, J. Early detection of melanoma progression by quantitative real-time RT-PCR analysis for multiple melanoma markers. Keio J. Med. 2008, 57, 57-64.
89. Cristofanilli, M.; Budd, G. T.; Ellis, M. J.; Stopeck, A.; Matera, J.; Miller, M. C.; Reuben, J. M.; Doyle, G. V.; Allard, W. J.; Terstappen, L. W.; Hayes, D. F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351, 781-791.
90. Fusi, A.; Ochsenreither, S.; Busse, A.; Rietz, A.; Keilholz, U. Stem cell marker nestin expression in peripheral blood of patients with melanoma. Br. J. Dermatol. 2010 DOI:10.1111/j.1365-2133.2010.09779.x.
91. Samija, I.; Luka, J.; Mari -Brozi, J.; Buljan, M.; Alajbeg, I.; Kovaevi, D.; Situm, M.; Kusi, Z. Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res. 2010, Mar 30. [Epub ahead of print].